I am delighted to see Dr, Michael Reardon will be the study chair of the impending trial. He is the co-principal investigator for the recent head-to-head trial against the incumbents for Boston Scientific’s Acurate neo2 TAVR which has gained CE Mark and is now progressing for FDA approval.
”Dr. Michael Reardon, Allison Family Distinguished Chair of Cardiovascular Research and Professor ofCardiothoracic Surgery at the Houston Methodist Hospital and Study Chair of the DurAVR® THV Pivotal Trialsaid, “We are building on a strong foundation of clinical evidence, and we remain committed to rigorousscientific evaluation as we progress toward the all-risk, head-to-head, DurAVR® registration trial.”
Not advice, DYOR
AVR Price at posting:
$6.95 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)